{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:27:34Z","timestamp":1791098854600,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.ymgme.2012.02.014","type":"journal-article","created":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T10:46:26Z","timestamp":1330598786000},"page":"83-91","source":"Crossref","is-referenced-by-count":21,"title":["Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model"],"prefix":"10.1016","volume":"106","author":[{"given":"Maria Fatima","family":"Macedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Quinta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia Sofia","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Clara","family":"Sa Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2012.02.014_bb0270","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/01.CIR.54.5.818","article-title":"Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies","volume":"54","author":"Desnick","year":"1976","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2012.02.014_bb0275","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0280","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.gim.0000200950.25118.dd","article-title":"Quantitative dysmorphology assessment in Fabry disease","volume":"8","author":"Ries","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0285","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2013replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0290","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0295","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0300","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2012.02.014_bb0050","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease\u2014a comprehensive review of the medical literature","volume":"12","author":"Lidove","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0305","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2009.08.002","article-title":"Cardiac challenges in patients with Fabry disease","volume":"141","author":"Weidemann","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0310","first-page":"1","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"0","author":"Warnock","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0065","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"Alpha-galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0315","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","article-title":"Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice","volume":"96","author":"Ohshima","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2008.09.001","article-title":"Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice","volume":"33","author":"Rodrigues","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0320","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cjca.2010.12.035","article-title":"Myocardial alterations in the murine model of fabry disease can be reversed by enzyme replacement therapy","volume":"27","author":"Rozenfeld","year":"2011","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0085","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00428-011-1051-8","article-title":"Kidney histologic alterations in alpha-galactosidase-deficient mice","volume":"458","author":"Valbuena","year":"2011","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ymgme.2012.02.014_bb0325","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice","volume":"68","author":"Ioannou","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0330","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"10.1016\/j.ymgme.2012.02.014_bb0335","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10038-006-0369-6","article-title":"Corrective effect on Fabry mice of yeast recombinant human alpha-galactosidase with N-linked sugar chains suitable for lysosomal delivery","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0340","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0345","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ymgme.2006.11.008","article-title":"Cellular and tissue distribution of intravenously administered agalsidase alfa","volume":"90","author":"Murray","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0350","doi-asserted-by":"crossref","first-page":"e15033","DOI":"10.1371\/journal.pone.0015033","article-title":"Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease","volume":"5","author":"Marshall","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2012.02.014_bb0355","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2010.08.006","article-title":"Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease","volume":"399","author":"Togawa","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1423-0127-17-26","article-title":"Characterization of Fabry mice treated with recombinant adeno-associated virus 2\/8-mediated gene transfer","volume":"17","author":"Choi","year":"2010","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0130","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.37.2.710","article-title":"Cardiomyocytes bind and activate native human prorenin : role of soluble mannose 6-phosphate receptors","volume":"37","author":"Saris","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ymgme.2012.02.014_bb0135","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/eje.0.1300265","article-title":"Identification and characterization of insulin-like growth factor I (IGF-I) and IGF-II\/mannose-6-phosphate (IGF-II\/M6P) receptors in bovine adrenal cells","volume":"130","author":"Weber","year":"1994","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0360","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0365","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1002\/eji.200425546","article-title":"Development of CD1d-restricted NKT cells in the mouse thymus","volume":"34","author":"Dao","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0150","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.immuni.2005.03.011","article-title":"Genetic evidence supporting selection of the Valpha14 iNKT cell lineage from double-positive thymocyte precursors","volume":"22","author":"Egawa","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.ymgme.2012.02.014_bb0370","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1084\/jem.20050456","article-title":"Characterization of the early stages of thymic NKT cell development","volume":"202","author":"Benlagha","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0375","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nri2904","article-title":"Presumed guilty: natural killer T cell defects and human disease","volume":"11","author":"Berzins","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0380","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1399-0039.2009.01256.x","article-title":"Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities","volume":"73","author":"Wu","year":"2009","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.ymgme.2012.02.014_bb0385","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1084\/jem.20060921","article-title":"Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases","volume":"203","author":"Gadola","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0390","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.immuni.2010.08.003","article-title":"Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells","volume":"33","author":"Darmoise","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.ymgme.2012.02.014_bb0395","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.2008.07380.x","article-title":"Anomalies in conventional T and invariant natural killer T-cell populations in Fabry mice but not in Fabry patients","volume":"143","author":"Balreira","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0400","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1126\/science.291.5504.664","article-title":"Glycolipid antigen processing for presentation by CD1d molecules","volume":"291","author":"Prigozy","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2012.02.014_bb0405","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/eji.200939639","article-title":"Development and maturation of invariant NKT cells in the presence of lysosomal engulfment","volume":"39","author":"Plati","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0410","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/eji.200737160","article-title":"Differential alteration of lipid antigen presentation to NKT cells due to imbalances in lipid metabolism","volume":"37","author":"Schumann","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0415","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1126\/science.1103440","article-title":"Lysosomal glycosphingolipid recognition by NKT cells","volume":"306","author":"Zhou","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2012.02.014_bb0205","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4049\/jimmunol.177.1.26","article-title":"Cutting edge: impaired glycosphingolipid trafficking and NKT cell development in mice lacking Niemann\u2013Pick type C1 protein","volume":"177","author":"Sagiv","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0210","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1084\/jem.20061562","article-title":"The Niemann\u2013Pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules and contributes to the thymic selection of NKT cells","volume":"204","author":"Schrantz","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0420","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-009-1060-9","article-title":"Leukocyte perturbation associated with Fabry disease","author":"Rozenfeld","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0425","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-5793(02)02491-2","article-title":"Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry","volume":"515","author":"Mills","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0430","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0022-1759(90)90407-M","article-title":"Isolation and flow cytometric analysis of the free lymphomyeloid cells present in murine liver","volume":"132","author":"Goossens","year":"1990","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ymgme.2012.02.014_bb0435","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1172\/JCI9711","article-title":"Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation","volume":"105","author":"Abe","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0440","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00431-009-0937-9","article-title":"Fabry disease in children and the effects of enzyme replacement treatment","volume":"168","author":"Pintos-Morell","year":"2009","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0240","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1084\/jem.20011786","article-title":"Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining","volume":"195","author":"Gumperz","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0245","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.4049\/jimmunol.168.7.3140","article-title":"Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells","volume":"168","author":"Takahashi","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0250","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20011908","article-title":"Distinct functional lineages of human V(alpha)24 natural killer T cells","volume":"195","author":"Lee","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0445","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1073\/pnas.0408288102","article-title":"Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion","volume":"102","author":"Schmieg","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0260","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1371\/journal.pbio.0030113","article-title":"Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids","volume":"3","author":"Geissmann","year":"2005","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ymgme.2012.02.014_bb0265","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00018-007-7007-0","article-title":"Antigen presentation by CD1 molecules and the generation of lipid-specific T cell immunity","volume":"64","author":"Bricard","year":"2007","journal-title":"Cell. Mol. Life Sci."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212000650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212000650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T22:43:16Z","timestamp":1713652996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719212000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1096719212000650"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2012.02.014","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}